Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Issuers

PRICED: Boots $1.25bn equiv 7NC3 sr sec notes 2-part, E650m 5.375% at 100, GBP375m 7.375% at 100

HYC US Market: Deal Flow - GeneralHYC European Market: Deal Flow - General

Boots Group Finco LP/The Boots Group Luxco Sarl (BOOTSFN) U$1.25bn (down from US$2bn) equivalent 144A/Reg S sr sec notes 2-part. B1/B+/BB (stable/stable/stable). Via GS (B&D EUR & GBP)/UBS (B&D US$) jt physical books/JPM/Citi/DB/WFS/Mizuho/PNC/RBC/CIBC/Citizens/Scotia/TD/BNP/FITB/TSI/USB jt books. No reg rights. List ISE. NY law. Settles 08/01 (T+10). 

- EUR650m (US$750m equivalent) (from minimum US$750m and US$750m equivalent) due 8/31/32 (7y). NC3 (8/31/28)(MWC B+50bp) then on 8/31/28 at 102.6875, 8/31/29 at 101.3438, and on 8/31/30 and thereafter at 100. Equity claw: 3y 40% at 105.375. Special call: 10% per year the first 3 years at 103. CoC at 101. Pays 2/28 and 8/31, starting 2/28/26. Denoms: 100x1. 144A ISIN: XS3134602401. IPT: 6.00% area. Revised IPT: 5.75%-6.00%. Price talk: 5.50%-5.75%. Final terms EUR650m (US$750m equiv) at 5.375%. Priced: 5.375% at 100. +297bp vs DBR 1.7% 08/15/32.

- GBP375m (US$500m equivalent) (from minimum US$500m and US$750m equivalent) due 8/31/32 (7y). NC3 (8/31/28) (MWC G+50bp) then on 8/31/28 at 103.6875, 8/31/29 at 101.8438, and on 8/31/30 and thereafter at 100. Equity claw:3y 40% at 107.375. Special call: 10% per year the first 3 years at 103. CoC at 101. Pays 2/28/and 8/31, starting 2/28/26. Denoms: 100x1.  144A ISIN: XS3134602740. IPT: 8.00% area. Revised IPT: 7.75%-8.00%. Price talk: 7.50%-7.75%. Final terms: GBP375m (US$500m equiv) at 7.375%. Priced: 7.375% at 100. +311bp vs vs UKT4.25% 6/7/32.

Dropped: US$500m due 2032 (7y). NC3 (MWC T+50bp). Equity claw:3y 40%. Special call: 10% per year the first 3 years at 103. CoC at 101. Denoms: 200x1. IPT: Mid-high 7s.

Total debt size increased to US$4.5b (from $4.25bn) equiv. Did investor call at 2pm UKT/9am NYT 07/15. Books closed at 5pm UKT/12pm NYT 07/17. Reconfirms due by 1pm UKT/8am NYT 07/18. Priced concurrently with the term loan, originally pricing 07/22. UOP: along with US$3.25bn (up from US$3bn and US$2.25bn) equivalent (US1.50bn (up from US$1bn minimum and US$750m), EUR1.075m (US$1.25bn equiv) (up from US$1bn minimum and US$1bn) equivalent in EUR, and GBP375m (US$500m equivalent) (from US$500m and US$500m) sr sec term loans, and US$950m (down from US$1.2bn) pfd equity via Goldentree, to fund the LBO of Boots, which will be spun off from Walgreens Boots Alliance (WBA) by Sycamore Partners for US$11.45 per share and one divested asset proceeds right (up to $3 per DAP right (or approx $2.7bn total) from the future monetization of VillageMD Business) for $10bn equity value or a potential total value of up to $23.7bn, including net debt and opioid settlements. (US$500m tranche moved to the US$ TLB, US$250m equivalent downsize in the GBP tranche was moved to the EUR TLB, and then the US$250m TLB upsize reduced the pfd equity). Sycamore will contribute US$2.5bn in equity. Biz: UK based pharmacy chain. (Acquisition announced 03/06/25).

Netroadshow direct link: https://urldefense.com/v3/__https:/www.netroadshow.com/nrs/home/*!/?show=4bad713c__;Iw!!O2kDR7mm-zSJ!p15OEkS-zfiqY6i4rcDyYdWZJg-8-EBKHRzujEPaZtlJQx-GRFJAbMJv4a0TOd2AHVJBQ3bQEbwCzx8$. Access code: 2025-Boots.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.